Core Insights - Bioventus reported a solid Q4 performance with revenue of $158 million, reflecting a 3% increase year-over-year and a 10% organic growth after adjusting for the Advanced Rehabilitation divestiture [7][11]. - The company highlighted strong performance in Pain Treatments, which grew 15% in Q4, driven by the DUROLANE product and a shift towards single-injection therapies [4][9]. - Management provided guidance for 2026, projecting net sales of $600–610 million and adjusted EPS of $0.73–0.77, indicating expected growth in both revenue and profitability [10][21]. International Performance - International revenue remained unchanged year-over-year in Q4, but organic growth was reported at 11% for the full year, attributed to improved commercial execution and talent additions [1]. - The timing of distributor orders impacted Q4 growth, which was noted by management [1]. Restorative Therapies - Revenue in Restorative Therapies declined by 26% due to the divestiture of Advanced Rehabilitation, but organic growth was still 10%, largely driven by strong performance from the EXOGEN product [2][9]. Surgical Solutions - Surgical Solutions saw a revenue growth of 3%, with Ultrasonics facing tough comparisons against a record high from the previous year [3]. - Generator revenue in Q4 was noted as the third-highest total ever for the company, indicating a solid foundation for future growth [3]. Pain Treatments - Pain Treatments revenue advanced by 15% in Q4, with a strong emphasis on the hyaluronic acid franchise and favorable demographics for knee osteoarthritis [4]. - The performance was significantly driven by volume, with DUROLANE leading the results [4]. Financial Performance - Adjusted EBITDA for the quarter was $37 million, a 30% increase year-over-year, with an adjusted EBITDA margin of 23%, up 490 basis points from the previous year [6][11]. - The company reported a quarterly record for cash from operations at $38 million, nearly double the prior-year quarter, contributing to a full-year cash flow of nearly $75 million, a 92% increase [13][14]. Balance Sheet and Leverage - Bioventus ended the quarter with $51 million in cash and $294 million in outstanding debt, with a reduction of $29 million in debt during the quarter [15]. - The net leverage ratio declined to below 2.5x, with expectations to be well below 2x by the end of 2026 [15]. 2026 Strategy and Investments - The company plans to allocate approximately $13 million in incremental investments across growth drivers such as PNS, PRP, Ultrasonics, and international expansion [17][18]. - Management expects the combination of PNS and PRP to contribute at least 200 basis points of growth in 2026, with further acceleration anticipated in 2027 [19]. Guidance and Expectations - For 2026, management expects Q1 to be below the implied guidance range, with growth anticipated to accelerate in Q2 and the second half of the year [22]. - The company does not anticipate any additional impact from U.S. dollar fluctuations for the year [25].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the Advanced Rehabilitation divestiture [23][24] - Adjusted EBITDA increased by $8 million to $37 million, representing a 30% increase year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points [24][27] - Cash flow from operations totaled $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full-year cash flow increase of 92% [28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [25] - Surgical solutions revenue grew by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [25] - Restorative therapies revenue declined by 26% due to the divestiture, but organic growth was 10% excluding this impact, driven by strong performance from EXOGEN [26] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged year-over-year, but organic growth was 10%, with an overall growth of 11% for the year [26] - The company expects to continue its positive momentum in international markets due to talent additions and improved commercial execution [26] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [6][7] - In 2026, the company plans to invest approximately $13 million in growth drivers, including PNS, PRP, Ultrasonics, and international business [13][16] - The focus will be on driving above-market growth, expanding profitability, and strengthening cash flow, with an expected EBITDA margin of approximately 20% for 2026 [19][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and its ability to deliver above-market revenue growth while increasing investments in growth drivers [20][66] - The company anticipates earnings growth to outpace revenue growth, driven by strong gross margins and disciplined resource allocation [19][30] Other Important Information - The company has refinanced its term loan, enhancing liquidity and driving interest expense savings [12] - The company expects cash from operations to range between $82 million and $87 million in 2026, an increase of approximately 10%-17% [30] Q&A Session Summary Question: Growth contribution year-over-year from price and thoughts on GELSYN-3 and SUPARTZ FX - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][36] Question: Assumptions by segment for 2026 growth - Pain treatments are expected to see mid to high single-digit growth, while restorative therapies are projected to grow low to mid-single digits [38][39] Question: Tailwind from favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [46] Question: Learnings from the PNS pilot phase and confirmation of 200 basis point growth - Positive feedback was received on the technology's power and ease of use, and management reaffirmed the expectation of a minimum of 200 basis points growth from PNS and PRP [48][50]

Bioventus (NasdaqGS:BVS) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Company ParticipantsCaitlin Cronin - Director - MedTech Equity ResearchDave Crawford - VP of Investor Relations and TreasurerMark Singleton - SVP and CFORob Claypoole - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMichael Petusky - Research AnalystRob ClaypooleGood day, and welcome to the Bioventus Q4 2025 earnings conference call. All participants will be in a listen-only mode. Should you ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the impact of the Advanced Rehabilitation divestiture [20][21] - Adjusted EBITDA for the quarter was $37 million, an increase of $8 million or 30% year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the previous year [21][22] - Cash flow from operations totaled approximately $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full year objective of nearly doubling cash flow from operations, achieving a 92% increase for the year [26][28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [23] - Surgical solutions revenue increased by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [23] - Restorative therapies revenue declined by 26% due to the divestiture of the Advanced Rehabilitation business, but organic growth was 10% excluding this impact [24] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged compared to the prior year, with organic growth climbing 10% [24] - The international segment achieved 11% organic growth for the year, supported by a new team and improved commercial execution [24] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [5][10] - In 2026, the company plans to invest approximately $13 million in growth drivers such as PNS, PRP, Ultrasonics, and international business [11][12] - The focus will be on driving above-market growth across core businesses, particularly the HA franchise, while also investing in marketing and R&D to support growth [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and strong foundation, indicating a focus on becoming a $1 billion leading med tech company [5][18] - The company anticipates earnings growth to outpace revenue growth, maintaining an EBITDA margin of approximately 20% for 2026 [17][18] - Management highlighted the importance of leveraging profitable growth to fund future growth drivers, emphasizing a long-term approach to business [40] Other Important Information - The company refinanced its term loan, enhancing liquidity and driving interest expense savings [10] - The company expects net sales for 2026 to range from $600 million to $610 million, with adjusted earnings per share projected at $0.73 to $0.77 [27][28] Q&A Session Summary Question: Growth contribution year-over-year from price in pain treatments - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][35] Question: Assumptions by segment for 2026 growth - Management expects low to mid-single digit growth in restorative therapies and mid to high single digit growth in the pain portfolio, with double-digit growth anticipated in surgical solutions [36][38] Question: Impact of favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [45] Question: Learnings from the PNS pilot phase - Positive feedback was received regarding the technology's power, size, and ease of use, with plans to scale the business aggressively based on these insights [48][50]

Agenda and Speakers Rob Claypoole President and Chief Executive Officer Update on Business and 2026 Priorities Fourth Quarter 2025 Financial Results March 5, 2026 Mark Singleton Senior Vice-President and Chief Financial Officer Q4 2025 Results 2026 Financial Guidance 2 Forward Looking Statements and Use of Estimates Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-K ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 BIOVENTUS INC. (Exact Name of Registrant as Specified in Its Chart ...

Financial Performance - Fourth quarter 2025 worldwide revenue totaled $157.9 million, a 10.0% increase on an organic basis, driven by double-digit growth in Pain Treatments and Surgical Solutions [4]. - Net income for Q4 2025 was $14.8 million, compared to a net loss of $0.4 million in the prior-year period, marking a significant turnaround [5]. - Adjusted EBITDA for Q4 2025 was $36.7 million, a 30% increase from $28.3 million in the prior-year period, attributed to higher organic revenue growth and improved gross margins [5]. - Full-year 2025 worldwide revenue was $568.1 million, a decrease of 0.9% compared to the prior year, but organic revenue grew by 7.5% [7]. - Full-year 2025 net income was $22.7 million, a recovery from a net loss of $36.1 million in the previous year [8]. - Fourth quarter cash from operations reached $38.0 million, a remarkable 97% increase compared to the prior-year period [10]. - For the three months ended December 31, 2025, net sales were $157.9 million, compared to $153.6 million for the same period in 2024 [37]. - The company reported a net income of $14.8 million for the three months ended December 31, 2025, compared to a net loss of $0.4 million for the same period in 2024 [37]. - Net income for the three months ended December 31, 2025, was $17,318 thousand, compared to a loss of $603 thousand in the same period of 2024, marking a significant turnaround [39]. - Adjusted EBITDA for the three months ended December 31, 2025, was $36,710 thousand, compared to $28,250 thousand in the same period of 2024, reflecting a year-over-year increase of 30.1% [55]. - The company reported a net income of $17.3 million for the three months ended December 31, 2025, resulting in a diluted EPS of $0.21 [60]. - For the year ended December 31, 2025, the reported GAAP gross profit was $388.2 million, with a gross margin of 68.3% [62]. - The non-GAAP net income for the year ended December 31, 2025, was $58.7 million, leading to an adjusted EPS of $0.68 [62]. Revenue Breakdown - Pain Treatments revenue for Q4 2025 was $79.7 million, reflecting a 15.1% increase driven by strong demand for hyaluronic acid therapies [12]. - Surgical Solutions revenue for Q4 2025 was $55.5 million, a 3.4% increase due to higher U.S. demand for Bone Graft Substitutes [12]. - Net sales for the year are projected to be between $600 million and $610 million, reflecting a growth of approximately 6% to 7% [29]. - Adjusted EPS is expected to be between $0.73 and $0.77, indicating an increase of approximately 7% to 13% [29]. - Cash from operations is projected to be between $82 million and $87 million [29]. Cash Flow and Liquidity - Bioventus reduced its debt by $29 million in Q4 2025, strengthening its balance sheet and improving liquidity [22]. - Total assets as of December 31, 2025, were $683.6 million, down from $728.0 million as of December 31, 2024 [34]. - Total liabilities decreased to $455.1 million as of December 31, 2025, from $542.4 million as of December 31, 2024 [34]. - The company reported a total cash and cash equivalents balance of $51,238 thousand at the end of the period, up from $41,582 thousand at the end of the previous year [39]. - Net cash from operating activities increased to $37,968 thousand for the three months ended December 31, 2025, up from $19,322 thousand in the prior year, representing a growth of 96.5% [39]. - The company’s net cash from investing activities was $(580) thousand for the three months ended December 31, 2025, compared to $24,104 thousand in the prior year, indicating a significant decrease due to fewer business sales [39]. - The company’s net cash from financing activities was $(28,447) thousand for the three months ended December 31, 2025, compared to $(42,855) thousand in the same period of 2024, showing an improvement in cash flow management [39]. Operational Efficiency - The company strengthened its executive leadership team with the addition of Megan Rosengarten as Senior Vice-President and General Manager of Peripheral Nerve Stimulation [29]. - The company recognized losses related to the refinancing of long-term debt, impacting overall financial performance [59]. - The company incurred a non-cash impairment charge of $33.9 million for intangible assets related to the divestiture of the Advanced Rehabilitation Business [59]. - Restructuring costs in 2025 were primarily associated with severance and consolidation of administrative functions, totaling $2.2 million [59]. - The company reported a change in working capital of $6,207 thousand for the three months ended December 31, 2025, compared to a negative change of $(2,108) thousand in the same period of 2024, indicating improved operational efficiency [39]. Risks and Challenges - Bioventus faces various risks including regulatory challenges, supply chain issues, and competition that could impact future growth and product commercialization [31].

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of $0.24 per diluted shareFourth quarter cash from operations of $38.0 million increased 97%2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “ ...

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-04 ...

Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors should consider buying NOK stock based on analysts' recommendations [1]